Atsetylsalytsylovaya acid, [magnesium hydroxide] | Cardiomagnyl tablets 75 + 15.2 mg 30 pcs.
Special Price
$15.52
Regular Price
$23.00
In stock
SKU
BID480983
Pharmacological action of the second group of the first group
Pharmacological action of the second group of the first group
Packing
30 pcs. - brown glass bottles (1) - packs of cardboard.
Pharmacological action
Cardiomagnyl has an antiplatelet effect, It is a non-steroidal anti-inflammatory drug. The anti-inflammatory effect is associated with irreversible inhibition of cyclooxygenase-1 due to the acetylation reaction. Thromboxane A2 under the influence of acetylsalicylic acid (ASA) decreases as a result of selective inhibition of its synthesis. There are probably other mechanisms for reducing platelet aggregation with ASA.
Magnesium hydroxide has a protective effect on the gastric mucosa, which is important when taking ASA.
ASA is completely absorbed when taken orally from the gastrointestinal tract. Hydrolysis to salicylic acid occurs with the participation of esterases in the liver, intestines and blood plasma. The half-life of ASA is 15 minutes, salicylic acid - 3 hours. An additional intake of ASA (more than 3 g) can lengthen the half-life of salicylic acid due to the complete saturation of the enzyme systems. The bioavailability of the ASA metabolite - salicylic acid - ranges from 80 to 100%. The bioavailability of ASA is approximately 70%, but this value is very variable due to presystem hydrolysis in the wall of the stomach, intestines and liver tissue. Magnesium hydroxide in cardiomagnyl does not affect the bioavailability of ASA.
Indications
Preventive therapy for increased platelet aggregation in: thrombosis and embolism, coronary heart disease, myocardial infarction, ischemic strokes and cerebrovascular accident, migraine.
Used for the prevention of thrombosis in cardiovascular surgery (in the postoperative period after coronary angioplasty, coronary artery bypass grafting).
Contraindications
• Propensity to bleeding or recent episode of bleeding (hemorrhagic diathesis, hemorrhagic stroke, hypothrombinemia, gastrointestinal bleeding, hemophilia)
• bronchial asthma in response to the administration of ASK
• allergy to the component) glucose-6-phosphate dehydrogenase
• renal failure
• taking methotrexate at a dose of more than 15 mg / week
• age under 18 years.
Use during pregnancy and lactation
The use of cardiomagnyl is contraindicated in 1 (fetal developmental abnormalities) and 3 (increased bleeding in the fetus, intraventricular hemorrhage in the fetus, premature closure of the oval duct of the fetus, abnormalities in the woman and pregnancy) and trimester. In the 2nd trimester, appoint with caution.
Interaction with other drugs: The combined use of a high dose of cardiomagnyl and oral anticoagulants potentiates the effect of the latter. Cardiomagnyl potentiates the effects of fibrinolytics, antiplatelet agents. Diuretic drugs (spironolactone) and antihypertensives reduce their effect when taking cardiomagnyl. Enhances the effects of chlorpropamide and methotrexate. The absorption of cardiomagnyl is significantly reduced with the use of antacids and sorbents.
Special instructions
Use with caution in case of gout and hyperuricemia (reduces uric acid excretion).
Do not use before surgery and in the postoperative period (risk of bleeding).
Patients with diabetes with prolonged use of cardiomagnyl require correction of hypoglycemic agents (ASA causes hypoglycemia).
Do not use with ibuprofen (leveling the therapeutic effect of ASA).
When taking glucocorticoids, it is possible to lower the level of salicylates in the blood plasma, after the cancellation of glucocorticoids, salicylates increase (risk of overdose).
While taking cardiomagnyl, monitoring of a clinical blood test is necessary.
Composition of
Cardiomagnyl:
Active components:
acetylsalicylic acid - 75 mg, magnesium hydroxide - 15.2 mg.
Auxiliary components:
corn and potato starch,
microcrystalline cellulose,
talc,
magnesium stearate,
hypromellose,
polyethylene glycol.
Product form:
Cardiomagnyl and cardiomagnyl forte - tablets,
film-coated, heart-shaped, in dark glass bottles of 30 and 100 pcs.
Dosage and administration of
1 tablet of cardiomagnyl forte or 2 tablets of cardiomagnyl (150 g ASA) on the first day of treatment, then 75 mg (1 tablet of cardiomagnyl) 1 time per day. The tablet is washed down with a small amount of water. If necessary, chew or crush tablets. It is recommended to eat after meals. The duration of treatment is determined by the doctor individually, depending on the clinic, indications and severity of the disease.
Side effects
Allergic reactions, bronchospasm, hemorrhagic stroke, bleeding from the gastrointestinal tract. Heartburn, dyspeptic disorders, irritable bowel syndrome, gastrointestinal ulcers, perforation of an existing gastrointestinal ulcer can occur. In a clinical blood test, eosinophilia, a decrease in platelet count, aplastic anemia, neutropenia, agranulocytosis are determined. In the coagulogram, hypoprothrombinemia is noted. Headache, tinnitus, drowsiness, dizziness are rarely observed.
Drug Interactions
With the simultaneous use of ASA enhances the action of the following drugs:
of methotrexate - due to a decrease in renal clearance and its displacement from association with heparin
proteins and indirect anticoagulants - due to impaired platelet function and displacement of indirect anticoagulants from association with
proteins of thrombolytic and antiplatelet drugs due to its decrease
hypoglycemic agents (insulin and sulfonylurea derivatives) - due to the hypoglycemic properties of ASA itself in high doses and displacement of sulfonylurea derivatives from connection with proteins
of valproic acid - due to its displacement from communication with proteins.
An additive effect is observed while taking ASA with ethanol (alcohol).
ASA weakens the action of uricosuric agents (benzbromarone) due to competitive tubular elimination of uric acid.
Strengthening the elimination of salicylates, systemic corticosteroids weaken their effect.
Antacids and colestyramine decrease absorption of the drug.
overdose
Tachypnoe develops overdose with cardio magnet overdose, bleeding time increases, nausea, anxiety, tinnitus, sweating, and hearing loss decrease. Vomiting masses contain streaks of blood. The dangerous dose is 150 mg / kg. In severe cases, ketoacidosis, heart rhythm disorders, hypoglycemia, acute cardiovascular failure, hyperventilation, acute respiratory failure, coma develops.
When signs of overdose are detected, the patient is hospitalized, gastric lavage, sorption enteral drugs are prescribed, and alkaline diuresis is provided, if necessary. Further symptomatic therapy is needed.
Storage Conditions
Storage should be protected from children, light and moisture.
Shelf life
Shelf life - 5 years at a temperature of no more than 25 РC
Deystvuyushtee substance
Atsetilsalitsilovaya Chisloth [Magna gidroksid]
Conditions from the drugstore
Without a prescription
dosage form
tablets
Takeda GmbH, Japan
Packing
30 pcs. - brown glass bottles (1) - packs of cardboard.
Pharmacological action
Cardiomagnyl has an antiplatelet effect, It is a non-steroidal anti-inflammatory drug. The anti-inflammatory effect is associated with irreversible inhibition of cyclooxygenase-1 due to the acetylation reaction. Thromboxane A2 under the influence of acetylsalicylic acid (ASA) decreases as a result of selective inhibition of its synthesis. There are probably other mechanisms for reducing platelet aggregation with ASA.
Magnesium hydroxide has a protective effect on the gastric mucosa, which is important when taking ASA.
ASA is completely absorbed when taken orally from the gastrointestinal tract. Hydrolysis to salicylic acid occurs with the participation of esterases in the liver, intestines and blood plasma. The half-life of ASA is 15 minutes, salicylic acid - 3 hours. An additional intake of ASA (more than 3 g) can lengthen the half-life of salicylic acid due to the complete saturation of the enzyme systems. The bioavailability of the ASA metabolite - salicylic acid - ranges from 80 to 100%. The bioavailability of ASA is approximately 70%, but this value is very variable due to presystem hydrolysis in the wall of the stomach, intestines and liver tissue. Magnesium hydroxide in cardiomagnyl does not affect the bioavailability of ASA.
Indications
Preventive therapy for increased platelet aggregation in: thrombosis and embolism, coronary heart disease, myocardial infarction, ischemic strokes and cerebrovascular accident, migraine.
Used for the prevention of thrombosis in cardiovascular surgery (in the postoperative period after coronary angioplasty, coronary artery bypass grafting).
Contraindications
• Propensity to bleeding or recent episode of bleeding (hemorrhagic diathesis, hemorrhagic stroke, hypothrombinemia, gastrointestinal bleeding, hemophilia)
• bronchial asthma in response to the administration of ASK
• allergy to the component) glucose-6-phosphate dehydrogenase
• renal failure
• taking methotrexate at a dose of more than 15 mg / week
• age under 18 years.
Use during pregnancy and lactation
The use of cardiomagnyl is contraindicated in 1 (fetal developmental abnormalities) and 3 (increased bleeding in the fetus, intraventricular hemorrhage in the fetus, premature closure of the oval duct of the fetus, abnormalities in the woman and pregnancy) and trimester. In the 2nd trimester, appoint with caution.
Interaction with other drugs: The combined use of a high dose of cardiomagnyl and oral anticoagulants potentiates the effect of the latter. Cardiomagnyl potentiates the effects of fibrinolytics, antiplatelet agents. Diuretic drugs (spironolactone) and antihypertensives reduce their effect when taking cardiomagnyl. Enhances the effects of chlorpropamide and methotrexate. The absorption of cardiomagnyl is significantly reduced with the use of antacids and sorbents.
Special instructions
Use with caution in case of gout and hyperuricemia (reduces uric acid excretion).
Do not use before surgery and in the postoperative period (risk of bleeding).
Patients with diabetes with prolonged use of cardiomagnyl require correction of hypoglycemic agents (ASA causes hypoglycemia).
Do not use with ibuprofen (leveling the therapeutic effect of ASA).
When taking glucocorticoids, it is possible to lower the level of salicylates in the blood plasma, after the cancellation of glucocorticoids, salicylates increase (risk of overdose).
While taking cardiomagnyl, monitoring of a clinical blood test is necessary.
Composition of
Cardiomagnyl:
Active components:
acetylsalicylic acid - 75 mg, magnesium hydroxide - 15.2 mg.
Auxiliary components:
corn and potato starch,
microcrystalline cellulose,
talc,
magnesium stearate,
hypromellose,
polyethylene glycol.
Product form:
Cardiomagnyl and cardiomagnyl forte - tablets,
film-coated, heart-shaped, in dark glass bottles of 30 and 100 pcs.
Dosage and administration of
1 tablet of cardiomagnyl forte or 2 tablets of cardiomagnyl (150 g ASA) on the first day of treatment, then 75 mg (1 tablet of cardiomagnyl) 1 time per day. The tablet is washed down with a small amount of water. If necessary, chew or crush tablets. It is recommended to eat after meals. The duration of treatment is determined by the doctor individually, depending on the clinic, indications and severity of the disease.
Side effects
Allergic reactions, bronchospasm, hemorrhagic stroke, bleeding from the gastrointestinal tract. Heartburn, dyspeptic disorders, irritable bowel syndrome, gastrointestinal ulcers, perforation of an existing gastrointestinal ulcer can occur. In a clinical blood test, eosinophilia, a decrease in platelet count, aplastic anemia, neutropenia, agranulocytosis are determined. In the coagulogram, hypoprothrombinemia is noted. Headache, tinnitus, drowsiness, dizziness are rarely observed.
Drug Interactions
With the simultaneous use of ASA enhances the action of the following drugs:
of methotrexate - due to a decrease in renal clearance and its displacement from association with heparin
proteins and indirect anticoagulants - due to impaired platelet function and displacement of indirect anticoagulants from association with
proteins of thrombolytic and antiplatelet drugs due to its decrease
hypoglycemic agents (insulin and sulfonylurea derivatives) - due to the hypoglycemic properties of ASA itself in high doses and displacement of sulfonylurea derivatives from connection with proteins
of valproic acid - due to its displacement from communication with proteins.
An additive effect is observed while taking ASA with ethanol (alcohol).
ASA weakens the action of uricosuric agents (benzbromarone) due to competitive tubular elimination of uric acid.
Strengthening the elimination of salicylates, systemic corticosteroids weaken their effect.
Antacids and colestyramine decrease absorption of the drug.
overdose
Tachypnoe develops overdose with cardio magnet overdose, bleeding time increases, nausea, anxiety, tinnitus, sweating, and hearing loss decrease. Vomiting masses contain streaks of blood. The dangerous dose is 150 mg / kg. In severe cases, ketoacidosis, heart rhythm disorders, hypoglycemia, acute cardiovascular failure, hyperventilation, acute respiratory failure, coma develops.
When signs of overdose are detected, the patient is hospitalized, gastric lavage, sorption enteral drugs are prescribed, and alkaline diuresis is provided, if necessary. Further symptomatic therapy is needed.
Storage Conditions
Storage should be protected from children, light and moisture.
Shelf life
Shelf life - 5 years at a temperature of no more than 25 РC
Deystvuyushtee substance
Atsetilsalitsilovaya Chisloth [Magna gidroksid]
Conditions from the drugstore
Without a prescription
dosage form
tablets
Takeda GmbH, Japan
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review